Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 9Head & Neck 1CNS 1

Conditions

Neuroblastoma 55Central Nervous System Neoplasms 53Brain Neoplasms 48Astrocytoma 30Glioblastoma 27Medulloblastoma 25Glioma 23Oligodendroglioma 21Gliosarcoma 14Optic Nerve Glioma 13Testicular Neoplasms 11Choroid Plexus Neoplasms 11Sarcoma 10Ovarian Neoplasms 10Neoplasms 10Rhabdoid Tumor 9Carcinoma, Non-Small-Cell Lung 9Testicular Germ Cell Tumor 7Teratoma 7Recurrence 7Neuroectodermal Tumors, Primitive, Peripheral 7Familial ependymoma 7Ependymoma 7Lung Neoplasms 6Spinal Cord Neoplasms 5Retinoblastoma 5Osteosarcoma 5Neuroectodermal Tumors, Primitive 5Lymphoma 5Liver Neoplasms 5

Interventions

selpercatinib 2alectinib 1Pemetrexed 1Gefitinib 1Erlotinib Hydrochloride 1Carboplatin 1AZD3759 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Respiratory Tract Diseases × Carboplatin × CNS × Clear all
NCT05241873 2025-02-10

(Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations

Blueprint Medicines Corporation

Phase 1 Terminated
103 enrolled
CNSThoracic

Adenocarcinoma, Brain Neoplasms, Bronchial Neoplasms, Carcinoma, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡